Screener
Theravance Biopharma TBPH EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Theravance Biopharma’s reported figures.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
FAQ
- What is Theravance Biopharma's EBITDA?
- Theravance Biopharma (TBPH) reported EBITDA of -$9.1M in Q1 2026.
- How has Theravance Biopharma's EBITDA changed year-over-year?
- Theravance Biopharma's EBITDA increased by 35.1% year-over-year, from -$14.02M to -$9.1M.
- What is the long-term trend for Theravance Biopharma's EBITDA?
- Over 4 years (2021 to 2025), Theravance Biopharma's EBITDA has grown at a -70.3% compound annual growth rate (CAGR), from -$252.98M to -$1.98M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Theravance Biopharma's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude